rapid onset, and can be precipitated by drugs, alcohol, caloric deprivation, infection, endocrine factors or stress (Kappas et al., 1989) . Therefore, early detection of carriers of the defective gene is important in the prevention of attacks, since carriers can be advised to avoid the precipitating factors. The condition of most carriers of the defective gene is clinically latent, and accurate diagnosis of carrier status is not always possible by conventional biochemical methods (Kappas et al., 1989) . The PBGD enzyme activity in red blood cells has been used for the clinical diagnosis of the disease, but there is an overlap between the affected and the normal values (Kappas et al., 1989; McColl et al., 1982) .
Determination of the gene abnormality itself is the best methods for the diagnosis and has been successful in many cases. To date, more than 30 different mutations have been reported (Daimon et al., 1993 (Daimon et al., , 1994 Delfau et al., 1990 Delfau et al., , 1991 Grandchamp et al., 1989a-c; Gu et al., 1992 Gu et al., , 1994 Scobie et al., 1990; Lee and Anvret, 1991; Lee et al., 1990; Llewellyn et al., 1992; Lundin et al., 1994; Mgone et al., 1992 Mgone et al., , 1993 Schreiber et al., 1994) . Although high prevalences have been reported for two mutations as the result of a founder effect (Lee et al., 1990; Lee and Anvret, 1991 ; Gu et al., 1993) , many of them were found only in very few families, indicating that AIP is very heterogeneous at the molecular level. Up to now, two mutations were reported in Japanese patients (Daimon et al., 1993 (Daimon et al., , 1994 , and those were not reported yet in any other population. We report in this manuscript another mutation of the gene found in a Japanese patient. The mutation was a point mutation C to T, in exon 8 of the gene resulting in an amino acid substitution in the protein.
A 20-year-old Japanese woman with AIP and 9 members of her family were studied. The diagnosis of the patient was established on the basis of clinical symptoms of the disease, increased excretion of 3-aminolevulinic acid (ALA) and PBG in urine. Except the patient, no other individual in her family has ever shown clinical symptoms corresponding to the disease. She lives in Ohfunato, Iwate, Japan.
RNA and DNA were extracted as written below. Peripheral blood mononuclear cells were isolated by Ficoll density centrifugation, and total cellular RNA was extracted from the cells according to the single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction (Chomczynski and Sacchi, 1987) . Genomic DNA was extracted from peripheral blood leukocytes as described by Sambrook eta!. (1989) .
RNAs and DNAs thus extracted were used to amplify the DNA fragments of interest as written below. About 1 ~g of total cellular RNA was reverse transcribed by incubation for 1 h at 37~ in 20 ~1 of reaction mixture containing 50 mM KC1, 10 mM Tris-HC1, pH 8.3, 2 mM MgC12, 1 mM dNTPs, 20 units of RNase inhibitor (Toyobo, Tokyo), 5 ~M of random hexamers and 200 units of M-MLV reverse transcriptase (US Biochemicals, Cleveland, Ohio, USA). The reaction was stopped by heating at 95~ for 5 min and quenching on ice. The cDNA thus synthesized was used to amplify the fragments of interest by PCR. The PCR was carried out in a total volume of 25 F1 solution containing 50 mM KC1, 10 mM Tris-HC1, pH 9.0, 0.1 ~ Triton X-100, 1.5 mM MgC12, 200 ~u.M dNTPs, 2.5 units of rTaq DNA polymerase (Takara, Tokyo), 1 FM of each primer, and either 5 ~,.1 of cDNA solution prepared as mentioned above or 250 ng of genomic DNA. The cDNA or genomic DNA sample was denatured at 94~ for 2 min and then amplified for 25 to 30 cycles. Each cycle consisted of 1 min at 94~ 1-2 min at 50-55~ and 2-3 min at 72~ Six 21mers were synthesized to amplify PBGD cDNA in the region spanning from exons 4 to 15. The oligomers were designed to match the reported cDNA sequence in exon 4 (the oligomer was designated P-3), exon 9 (P-53), and exon 10 (P-55) for the sense primers, and in exon 9 (P-21), exon 12 (P-54), and exon 15 (P-56) for the anti-sense primers (shown in Fig. 1) .
The nucleotide sequence of the DNA fragments amplified were determined by direct sequencing. The cDNA fragments were amplified with the primer sets, P-3 and P-21, P-53 and P-54, and P-55 and P-56. The single-stranded cDNA fragments were then synthesized from the amplified double-stranded cDNA fragments by the method of asymmetric PCR. The single-stranded cDNA fragments were used as the templates for dideoxy sequencing under thermal cycling conditions using Tth DNA polymerase. We used Cycle Sequencing Kit from Pharmacia LKB Biotechnology (Tokyo). The PCR primers were used also as the sequencing primers. The details of these methods mentioned above were the same previously reported Primers used for PCR amplification and direct sequencing are shown in relation to the housekeeping mRNA of porphobilinogen deaminase (PBGD). The boxes in the map indicate exons. The housekeeping mRNA does not contain the region from the exon 2 of the PBGD gene as a result of alternative splicing. The initiation codon "ATG" for the housekeeping mRNA and the termination codon "TAA" were shown in the map. The forward and reverse arrows stand for sense and anti-sense primers, respectively. The details of the nucleotide sequence of the primers are shown below the map. (Daimon et al., 1993 (Daimon et al., , 1994 . The mutation found can be detected easily by restriction analysis of the PCR products. The genomic DNA fragment containing the mutation site was amplified by PCR using the primers M-1 and M-2. The mutation does not change any restriction enzyme recognition site. Therefore, the primer M-2 was made to contain one mismatch with the original sequence and introduce HhaI restriction site. The restriction enzyme HhaI cuts the amplified genomic DNA fragment derived from the normal allele and the mutation abolishes the site. The details of the primers are as follows, M-l; 5'-ACCATCGGAGCCATCTGCAA-3', and M-2; 5'-ACAA-CAGCATCATGAGGGTTTTCGC-3'. These primers are the same primers that Gu XF reported as primers PHE7 and P H E H H A (Gu et al., 1993) . The amplified genomic DNA fragments were digested for 3-6 h with HhaI restriction enzyme (Takara, Tokyo) as recommended by the supplier. The restriction enzyme-digested samples were electrophoresed in a 5 ~ polyacrylamide gel with Tris-Borate EDTA (TBE) buffer, and the bands were visualized by ethidium bromide staining under UV light. Genomic DNAs from 9 other individuals of the patients family as well as the patient were used for this analysis.
We used 6 primers to amplify the PBGD cDNA in the region corresponding to exons 4 to 15 (shown in Fig. 1 ). Direct sequencing of the amplified cDNA fragments from the patient revealed a single base substitution C to T in exon 8 of the PBGD gene at position 346 of the housekeeping cDNA from the translation initiation codon ATG. The sequencing ladder of the anti-sense strand around the mutation in exon 8 showed double bands at the second nucleotide of exon 8 (position 346 from the initiation codon) (Fig. 2) . This result clearly indicated that the patient Fig. 2 . Direct sequencing analysis of the amplified cDNA fragment from the AlP patient.
Nucleotide sequence around the mutation are shown. The position of the mutation is shown as double bands in the autoradiogram and indicated at the left as well.
Jpn J Human Genet is heterozygous for the normal allele and the mutant allele, which has a single base substitution C to T in exon 8 of the gene. We also used several other primers to amplify the genomic D N A fragments containing the mutation, and the direct sequencing of the amplified genomic D N A confirmed the existence of the mutant in the genome (data not shown). This mutation resulted in an Arg 116 to Trp substitution in the abnormal protein. The mutation does not change any restriction enzyme recognition site. So, we used PCR-primer introduced restriction analysis method as previously reported (Gu et al., 1993) , to detect the asymptomatic carrier of the mutant in the family. The mutagenic primer "M-2" introduced the HhaI restriction site in the amplified product, which was abolished by the presence of the mutation. Therefore, the HhaI digestion of the amplified genomic D N A fragment of the carrier produce the abnormal fragment of 280 bp, as well as the normal fragments of 260 and 20 bp. This analysis clearly revealed that the mutant allele was inherited from her father and 3 other members of her family share the mutant (Fig. 3).
The mutation was happened to be the same that Lee et al. (1990) reported. They found the mutation in a Swedish patient and reported that cDNA clones bearing only this single base change relative to the normal sequence failed to produce the enzymatic activity when expressed in a bacterial system. This results supported that the mutation in exon 8 is not a neutral polymorphism, but responsible for III Fig. 3 . Family tree of the AIP patient (III-3) and PCR-primer introduced restriction analysis. The genomic DNAs were amplified with primers M-1 and M-2, and analyzed as described in the manuscript. Lanes 1-10; DNAs from III-1, III-2, III-3, II-1, II-2, II-3, II-4, lb5, II-6, and I-2, respectively. The bands determined are indicated by the arrow. HhaI cuts the PCR product of 280 bp from normal allele into two fragments of 260 and 20 bp. Twenty bp fragment is not detected on the acrylamide gel.
AIP. Later on, the same mutation was reported by Gu et al. (1993) as a common mutation in the patients from the Netherlands. They reported that 15 out of 49 Dutch and one out of 33 French patients examined have the same mutation. Furthermore, 10 out of 15 of the Dutch families with the mutation were located in the mid-eastern part of the country. So, it is assumed that the mutation was originally happened in a patient in the mid-eastern part of the Netherlands, then became a common mutation in the country as the result of a founder effect, and spread to the nearby countries such as Sweden and France. But, in our case, it might be more reasonable to say that the mutation was happened de novo in an ancestor of her family, since no evidence supports that the family is related to any individuals from the Netherlands. A question, whether the mutation found can be a common mutation in Japanese patients as in Dutch patients or not, has to be solved. Because, every patients can be analyzed for the mutation before examined for the gene abnormalities specific in each case, if the mutation turned out to be a common mutation and therefore is expected to be found in high frequency. We believe that this report will facilitate other researchers to examine many other AIP patients for the mutation, and therefore eventually bring the answer to the question.
